Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment

被引:1
|
作者
Schulz, G. B. [1 ]
Stief, C. G. [1 ]
Schlenker, B. [1 ]
机构
[1] Klinikum Ludwig Maximilians Univ LMU Munchen, Urol Klin & Poliklin, Campus Grosshadern,Marchioninistr 15, D-81377 Munich, Germany
来源
UROLOGE | 2019年 / 58卷 / 09期
关键词
Urinary bladder neoplasms; Tumor surveillance; Urothelial carcinoma; Tumor recurrence; Urine cytology; RADICAL CYSTECTOMY; UROTHELIAL CARCINOMA; URETHRAL RECURRENCE; TRACT RECURRENCE; RISK-FACTORS; REMNANT UROTHELIUM; TUMOR RECURRENCE; OUTCOMES; DIVERSION; SURVIVAL;
D O I
10.1007/s00120-019-1012-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Follow-up care of patients with muscle-invasive bladder cancer is subdivided into oncological and functional surveillance. More than 80% of local relapses and distant metastases occur within the first 2 years. Recurrences in the remnant urothelium also occur several years after radical cystectomy. Urinary cytology and a computed tomography (CT) scan of the abdomen and thorax including a urography phase are the standard diagnostics for tumor follow-up. There is no clear evidence for a survival benefit for the detection of asymptomatic vs. symptomatic recurrences. After partial cystectomy or trimodal treatment, there is no established follow-up schedule; however, the relatively high incidence of intravesical recurrences should be considered as there are curative treatment approaches including salvage cystectomy. Functional surveillance, which should be carried out lifelong, encompasses prevention and diagnostics of metabolic complications, urethral/ureteral strictures, problems with the urinary stoma, urinary incontinence, sexual dysfunction and urinary tract infections.
引用
收藏
页码:1093 / 1106
页数:14
相关论文
共 50 条
  • [1] Survival after curative treatment of muscle-invasive bladder cancer
    Fossa, SD
    Aass, N
    Ous, S
    Waehre, H
    Ilner, K
    Hannisdal, E
    ACTA ONCOLOGICA, 1996, 35 : 59 - 65
  • [2] Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review
    Kaufmann, Ernest
    Aeppli, Stefanie
    Arnold, Winfried
    Balermpas, Panagiotis
    Beyer, Joerg
    Bieri, Uwe
    Cathomas, Richard
    de Bari, Berardino
    Dressler, Marco
    Engeler, Daniel S.
    Erdmann, Andreas
    Gallina, Andrea
    Gomez, Silvia
    Guckenberger, Matthias
    Herrmann, Thomas R. W.
    Hermanns, Thomas
    Ilaria, Lucca
    John, Hubert
    Kessler, Thomas M.
    Klein, Jan
    Laouiti, Mohamed
    Lauffer, David
    Mattei, Agostino
    Muntener, Michael
    Nguyen, Daniel
    Niederberger, Philipp
    Papachristofilou, Alexandros
    Prause, Lukas
    Reinhardt, Karsten
    Salati, Emanuela
    Sebe, Philippe
    Shelan, Mohamed
    Strebel, Raeto
    Templeton, Arnoud J.
    Vogl, Ursula
    Wettstein, Marian S.
    Zihler, Deborah
    Zilli, Thomas
    Zwahlen, Daniel
    Roth, Beat
    Fankhauser, Christian
    WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
  • [3] Long term follow-up after radiotherapy for muscle-invasive bladder cancer
    Cooke, PW
    Wallace, DMA
    Dunn, J
    Bathers, S
    Latief, T
    James, ND
    BRITISH JOURNAL OF CANCER, 1998, 78 : 10 - 10
  • [4] Nachsorge des muskelinvasiven Harnblasenkarzinoms nach kurativer TherapieFollow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment
    G. B. Schulz
    C. G. Stief
    B. Schlenker
    Der Urologe, 2019, 58 : 1093 - 1106
  • [5] Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer
    Kusaka, Ayumu
    Hatakeyama, Shingo
    Hosogoe, Shogo
    Hamano, Itsuto
    Iwamura, Hiromichi
    Fujita, Naoki
    Fukushi, Ken
    Narita, Takuma
    Hagiwara, Kazuhisa
    Yamamoto, Hayato
    Tobisawa, Yuki
    Yoneyama, Tohru
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ito, Hiroyuki
    Yoshikawa, Kazuaki
    Kawaguchi, Toshiaki
    Ohyama, Chikara
    ONCOTARGET, 2017, 8 (39) : 65492 - 65505
  • [6] RISK-STRATIFIED SURVEILLANCE AND COST EFFECTIVENESS OF FOLLOW-UP AFTER RADICAL CYSTECTOMY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER
    Kusaka, Ayumu
    Hatakeyama, Shingo
    Iwamura, Hiromichi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ito, Hiroyuki
    Yoshikawa, Kazuaki
    Kawaguchi, Toshiaki
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2018, 199 (04): : E618 - E618
  • [7] Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network
    Zuiverloon, Tahlita C. M.
    van Kessel, Kim E. M.
    Bivalacqua, Trinity J.
    Boormans, Joost L.
    Ecke, Thorsten H.
    Grivas, Petros D.
    Kiltie, Anne E.
    Liedberg, Fredrik
    Necchi, Andrea
    van Rhijn, Bas W.
    Roghmann, Florian
    Sanchez-Carbayo, Marta
    Schmitz-Draeger, Bernd J.
    Wezel, Felix
    Kamat, Ashish M.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (09) : 423 - 431
  • [8] The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy
    Hellenthal, Nicholas J.
    Ramirez, Michelle L.
    Evans, Christopher P.
    White, Ralph W. deVere
    BJU INTERNATIONAL, 2010, 105 (04) : 485 - 488
  • [9] Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
    Moller, Christina Tanem
    Fossa, Sophie D.
    Tafjord, Gunnar
    Babigumira, Ronnie
    Berge, Viktor
    Andreassen, Bettina Kulle
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (03) : 214 - 220
  • [10] Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer.
    Hatakeyama, Shingo
    Kusaka, Ayumu
    Hosogoe, Shogo
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)